Terms: = Leukemia AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254
1786 results:
1. Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.
Hu Z; Yang Y; Li J; Hu Z
Hematology; 2024 Dec; 29(1):2346965. PubMed ID: 38687637
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical Characteristics and Prognosis of Acute Myeloid leukemia Patients with
Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Molecular Profiling of npm1-Mutated Acute Myeloid leukemia Using RNAseq Approach.
Petiti J; Pignochino Y; Schiavon A; Giugliano E; Berrino E; Giordano G; Itri F; Dragani M; Cilloni D; Lo Iacono M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612443
[TBL] [Abstract] [Full Text] [Related]
4. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia.
Zhang LQ; Liang YC; Wang JX; Zhang J; La T; Li QZ
Comput Biol Med; 2024 May; 173():108396. PubMed ID: 38574529
[TBL] [Abstract] [Full Text] [Related]
5. Differential prognostic values of the three AKT isoforms in acute myeloid leukemia.
Corre E; Soum C; Pfeifer R; Bessière C; Dailhau S; Marbœuf C; Meggetto F; Touriol C; Récher C; Bousquet M; Pyronnet S
Sci Rep; 2024 Mar; 14(1):7070. PubMed ID: 38528080
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical analysis of allogeneic hematopoietic stem cell transplantation for seven cases of acute myeloid leukemia with BCR::ABL1 fusion].
Hao MZ; Zhao XL; Zhang XY; Shi YY; Gong M; Zhang LN; Chen SL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):995-1000. PubMed ID: 38503522
[No Abstract] [Full Text] [Related]
8. Regulation of HOX gene expression in AML.
Khan I; Amin MA; Eklund EA; Gartel AL
Blood Cancer J; 2024 Mar; 14(1):42. PubMed ID: 38453907
[TBL] [Abstract] [Full Text] [Related]
9. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Fiskus W; Piel J; Collins M; Hentemann M; Cuglievan B; Mill CP; Birdwell CE; Das K; Davis JA; Hou H; Jain A; Malovannaya A; Kadia TM; Daver N; Sasaki K; Takahashi K; Hammond D; Reville PK; Wang J; Loghavi S; Sen R; Ruan X; Su X; Flores LB; DiNardo CD; Bhalla KN
Blood; 2024 May; 143(20):2059-2072. PubMed ID: 38437498
[TBL] [Abstract] [Full Text] [Related]
10. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
11. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
Bouligny IM; Murray G; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Ho T; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Med Oncol; 2024 Feb; 41(3):80. PubMed ID: 38396145
[TBL] [Abstract] [Full Text] [Related]
12. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical Significance of Genetic and Molecular Changes in Primary Myeloid Sarcoma].
Jiang YJ; Zhang CF; Wang HX; Zhao L; Zhang FF; Han XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):27-32. PubMed ID: 38387895
[TBL] [Abstract] [Full Text] [Related]
14. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia.
Paterno G; Palmieri R; Tesei C; Nunzi A; Ranucci G; Mallegni F; Moretti F; Meddi E; Tiravanti I; Marinoni M; Page C; Fagiolo S; Buzzatti E; Secchi R; Gurnari C; Maurillo L; Buccisano F; Venditti A; Del Principe MI
Thromb Res; 2024 Apr; 236():30-36. PubMed ID: 38387301
[TBL] [Abstract] [Full Text] [Related]
15. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract] [Full Text] [Related]
16. Postinduction molecular MRD identifies patients with npm1 AML who benefit from allogeneic transplant in first remission.
Othman J; Potter N; Ivey A; Jovanovic J; Runglall M; Freeman SD; Gilkes A; Thomas I; Johnson S; Canham J; Cavenagh J; Kottaridis P; Arnold C; Ommen HB; Overgaard UM; Dennis M; Burnett A; Wilhelm-Benartzi C; Dillon R; Russell NH
Blood; 2024 May; 143(19):1931-1936. PubMed ID: 38364112
[TBL] [Abstract] [Full Text] [Related]
17. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Severens JF; Karakaslar EO; van der Reijden BA; Sánchez-López E; van den Berg RR; Halkes CJM; van Balen P; Veelken H; Reinders MJT; Griffioen M; van den Akker EB
Leukemia; 2024 Apr; 38(4):751-761. PubMed ID: 38360865
[TBL] [Abstract] [Full Text] [Related]
18. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Tarlock K; Gerbing RB; Ries RE; Smith JL; Leonti A; Huang BJ; Kirkey D; Robinson L; Peplinksi JH; Lange B; Cooper TM; Gamis AS; Kolb EA; Aplenc R; Pollard JA; Alonzo TA; Meshinchi S
Blood Adv; 2024 May; 8(9):2094-2103. PubMed ID: 38295280
[TBL] [Abstract] [Full Text] [Related]
[Next]
